A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Part of paid clinical trials in Lancaster, California.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT06869551
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Juvenile Psoriatic Arthritis
Eligibility Criteria
- Sex
- ALL
- Age
- 5 Years - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- Deucravacitinib — DRUGSpecified dose on specified days
- Placebo — OTHERSpecified dose on specified days
Study Details
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Key Dates
- Start date
- Mar 13, 2025
- Status verified
- Jun 2026
- Primary completion
- Mar 6, 2030
- Completion
- Mar 4, 2031
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A
- Placebo Comparator: Arm B
Primary Outcome Measure
Time to first flare during the withdrawal period [ Time Frame: From week 16 up to week 42 ]
Central Contacts
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
- First line of the email MUST contain NCT # and Site #.
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Local Institution - 0038 | Lancaster | California | 93534 | - |
| Local Institution - 0020 | Chicago | Illinois | 60611 | - |
| Local Institution - 0023 | Indianapolis | Indiana | 46202 | - |
| Local Institution - 0059 | North New Hyde Park | New York | 11040 | - |
| Local Institution - 0065 | Cincinnati | Ohio | 45229 | - |
| Local Institution - 0066 | Cleveland | Ohio | 44109 | - |
| Local Institution - 0036 | Austin | Texas | 78723 | - |
Find similar trials in Lancaster, CA
Related Studies
- A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabPHASE3 · Recruiting · AbbVie · Little Rock, Arkansas
- Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).PHASE1 · Recruiting · Novartis Pharmaceuticals · Gainesville, Florida